Effects of Intestinal Microbial–Elaborated Butyrate on Oncogenic Signaling Pathways

  title={Effects of Intestinal Microbial–Elaborated Butyrate on Oncogenic Signaling Pathways},
  author={Jiezhong Chen and Kong-Nan Zhao and L. Vitetta},
The intestinal microbiota is well known to have multiple benefits on human health, including cancer prevention and treatment. The effects are partially mediated by microbiota-produced short chain fatty acids (SCFAs) such as butyrate, propionate and acetate. The anti-cancer effect of butyrate has been demonstrated in cancer cell cultures and animal models of cancer. Butyrate, as a signaling molecule, has effects on multiple signaling pathways. The most studied effect is its inhibition on histone… 

Figures from this paper

Short-Chain Fatty Acids: A Soldier Fighting Against Inflammation and Protecting From Tumorigenesis in People With Diabetes

It is hypothesize that lower levels of microbial SCFAs resulted from gut dysbiosis in diabetic individuals, enhance microbial translocation, and increase the inflammatory responses, inducing tumorigenesis ulteriorly.

Remodelling of colorectal cancer cell signaling by microbiota and immunity in diabetes.

The pathways altered by defects in the immune response and microbiota that may link T2D to CRC development are discussed and animal models developed to study the relationships between T1D and CRC in the context of microbiota and immune system are discussed.

Butyrate Protects Pancreatic Beta Cells from Cytokine-Induced Dysfunction

Butyrate prevents pro-inflammatory cytokine-induced beta cell dysfunction in vitro and upregulated the expression of secretion/transport-related genes and downregulated inflammatory genes induced by IL-1β in mouse islets.

Review: Effect of Gut Microbiota and Its Metabolite SCFAs on Radiation-Induced Intestinal Injury

The alterations of gut microbiota after radiotherapy are emphasized and the alterations of SCFAs-producing bacteria andSCFAs are highlighted to explore the mechanisms of radiation-induced intestinal injury from the perspective of Gut microbiota and its metabolite SCFas.

Gut Metabolites and Breast Cancer: The Continuum of Dysbiosis, Breast Cancer Risk, and Potential Breast Cancer Therapy

Despite the promising evidence supporting the anticancer action of gut metabolites on different cancer types, the molecular mechanisms of action of this activity are not well established, especially against breast cancer and warrant further investigation.

Immunomodulation by Gut Microbiome on Gastrointestinal Cancers: Focusing on Colorectal Cancer

The current knowledge on the major immune cells and gut microbiome interactions is addressed and the underlying mechanisms of immune dysregulation caused by gut microbiota on four major cancerous pathways, inflammation, cellular proliferation, apoptosis, and metastasis are highlighted.

Microbial-Derived Tryptophan Catabolites, Kidney Disease and Gut Inflammation

The use of biotics (prebiotics, probiotics, synbiotics) as a means to increase the presence of beneficial short-chain fatty acids (SCFAs) to achieve intestinal homeostasis is discussed.

The interplay between anticancer challenges and the microbial communities from the gut.

A review of literature focusing on the antimicrobial effects of anticancer chemotherapy, their impact on mutagenesis in bacteria, and the perspectives of using bacteria-based tools to help in the diagnostic and treatment of cancer.

Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications

The gut microbiota dysregulation is a feature of NAFLD, and the signatures of gut microbiota are associated with the severity of the disease through altered bacterial metabolites.



Butyrate suppresses colonic inflammation through HDAC1-dependent Fas upregulation and Fas-mediated apoptosis of T cells.

It is shown that colonic mucosa from patients with UC exhibit increased signal transducer and activator of transcription 1 (STAT1) activation, and this STAT1 hyperactivation is correlated with increased T cell infiltration, suggesting that butyrate delivers a double hit: induction of T cell apoptosis to eliminate the source of inflammation and suppression of IFN-γ-mediated inflammation in colonic epithelial cells, to suppress colonic inflammation.

Opposing effects of butyrate and bile acids on apoptosis of human colon adenoma cells: differential activation of PKC and MAP kinases

The cellular basis of the effects of butyrate and the secondary bile acid ursodeoxycholic acid (UDCA) on signalling pathways known to regulate apoptosis using AA/C1 cells was examined.

Inhibition of interferon γ signaling by the short chain fatty acid butyrate

Butyrate negatively regulates mucosal inflammation through the inhibition of IFN-;/STAT1 signaling, and abnormal activity of STAT1 is associated with human malignancies and intestinal inflammatory diseases.

A gnotobiotic mouse model demonstrates that dietary fiber protects against colorectal tumorigenesis in a microbiota- and butyrate-dependent manner.

The results, which link diet and microbiota to a tumor-suppressive metabolite, provide insight into conflicting epidemiologic findings and suggest that probiotic/prebiotic strategies can modulate an endogenous HDAC inhibitor for anticancer chemoprevention without the adverse effects associated with synthetic HDAC inhibitors used in chemotherapy.

Butyrate-Induced Differentiation of Colon Cancer Cells Is PKC and JNK Dependent

It is suggested that butyrate could influence the colonocyte differentiation via modulation of the activity of cellular protein kinases and signal transduction.

Effects of the intestinal microbial metabolite butyrate on the development of colorectal cancer

The recent research progresses in the effect of gut microbiota imbalance and the decrease in intestinal microbial metabolite butyrate caused by unbalanced diet on CRC development are summarized, and the mechanisms ofbutyrate-induced anti-CRC activities are discussed, which may guide people to prevent CRC by improving diet structures.